講演情報
[OE1-3]口腔癌の新規バイオマーカー、分子標的候補HJURPの解析
○Tsevegjav Bayarbat1,2, 高野 淳1,2,3, 祝 銘1,2, 吉武 義恭4, 篠原 正徳4, 醍醐 弥太郎1,2,3 (1.滋賀医大・腫内/臨床腫瘍学, 2.滋賀医大・先端がん研究センター, 3.東大・医科研・抗体ワクチンセンター, 4.熊大・歯科口腔外科)
Based on the gene expression database and subsequent screening for target molecules, we identified Holliday junction recognition protein (HJURP) as a prognostic biomarker and therapeutic target for oral cancer. HJURP was highly expressed in the majority of oral cancers compared to normal oral tissues as detected by real-time qPCR and western blotting. HJURP protein was mainly localized in the nucleus of oral cancer cells as observed by immunocytochemical staining. Tissue microarray analysis showed that HJURP was expressed in 67.8% of 152 oral cancers, but it was hardly expressed in normal oral tissues. Positive HJURP expression was associated with poor clinical outcome of oral cancer patients (P=0.003, log-rank test). A multivariate analysis indicated that HJURP expression was an independent prognostic factor for patients with oral cancer. Knockdown of endogenous HJURP expression by siRNAs significantly inhibited the oral cancer cell growth and induced senescence of oral cancer cells. In contrast, exogenous expression of HJURP promoted oral cancer growth. Blocking peptide inhibited the binding of HJURP to CENP-A and significantly decreased the oral cancer cell growth. Since HJURP could be a potential prognostic biomarker and molecular target for oral cancer, we suggest inhibiting HJURP-CENP-A interaction could be one of the promising approaches for oral cancer treatment.